Potentially modifiable factors affecting the progression of autosomal dominant polycystic kidney disease

Clinical Journal of the American Society of Nephrology

Volumn 6, Issue 3, 2011, Pages 640-647

  Torres, Vicente E ^a   Grantham, Jared J ^b   Chapman, Arlene B ^c   Mrug, Michal ^d   Bae, Kyongtae T ^e   King Jr , Bernard F ^a   Wetzel, Louis H ^b   Martin, Diego ^c   Lockhart, Mark E ^d   Bennett, William M ^f   Moxey Mims, Marva ^g   Abebe, Kaleab Z ^e   Lin, Yan ^e   Bost, James E ^e  

^a Mayo Clinic   (United States)

^b UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^e UNIVERSITY OF PITTSBURGH   (United States)

^f Northwest Renal Clinic   (United States)

^g NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; IOTALAMATE SODIUM;

ADULT; ARTICLE; AUTOSOMAL DOMINANT DISORDER; AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE; BODY SURFACE; CREATININE CLEARANCE; DISEASE COURSE; FEMALE; HUMAN; KIDNEY POLYCYSTIC DISEASE; MAJOR CLINICAL STUDY; MALE; OSMOLALITY; SODIUM EXCRETION;

ADULT; AGE FACTORS; CHOLESTEROL, HDL; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; GLOMERULAR FILTRATION RATE; HUMANS; IOTHALAMIC ACID; KIDNEY; LINEAR MODELS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NATRIURESIS; ORGAN SIZE; OSMOLAR CONCENTRATION; PHENOTYPE; POLYCYSTIC KIDNEY, AUTOSOMAL DOMINANT; PROGNOSIS; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; UNITED STATES;

EID: 79953011165     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.03250410     Document Type: Article

References (33)

1. Chapman A, Guay-Woodford LM, Grantham JJ, Torres V, Bae K, Baumgarten D, Kenney P, King B, Glockner J, Wetzel L, Brummer M, O'Neill C, Robbin M, Bennett W, Klahr S, Hirschman G, Kimmel P, Thompson P, Miller J: Renal structure in early autosomal dominant polycystic kidney disease (ADPKD): the Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP) Cohort. Kidney Int 64: 1035-1045, 2003 (Pubitemid 37013840)
2. Grantham JJ, Torres VE, Chapman AB, Guay-Woodford LM, Bae KT, King BF Jr, Wetzel LH, Baumgarten DA, Kenney PJ, Harris PC, Klahr S, Bennett WM, Hirschman GN, Meyers CM, Zhang X, Zhu F, Miller JP: Volume progression in polycystic kidney disease. N Engl J Med 354: 2122-2130, 2006 (Pubitemid 43736612)
3. King BF, Torres VE, Brummer ME, Chapman AB, Bae KT, Glockner JF, Arya K, Felmlee JP, Grantham JJ, Guay-Woodford LM, Bennett WM, Klahr S, Hirschman GH, Kimmel PL, Thompson PA, Miller JP: Magnetic resonance measurements of renal blood flow as a marker of disease severity in autosomal-dominant polycystic kidney disease. Kidney Int 64: 2214-2221, 2003 (Pubitemid 37449557)
4. Rule AD, Torres VE, Chapman AB, J, GJ, Guay-Woodford LM, Bae KT, Klahr S, Bennett WM, Meyers CM, Thompson PA, Miller JP, CRISP: Comparison of methods for determining renal function decline in early autosomal dominant polycystic kidney disease: The consortium of radiologic imaging studies of polycystic kidney disease cohort. J Am Soc Nephrol 17: 854-862, 2006
5. Torres VE, King BF, Chapman AB, Brummer ME, Bae KT, Glockner JF, Arya K, Risk D, Felmlee JP, Grantham JJ, Guay-Woodford LM, Bennett WM, Klahr S, Meyers CM, Zhang X, Thompson PA, Miller JP: Magnetic resonance measurements of renal blood flow and disease progression in autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol 2: 112-120, 2007
6. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D: A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 130: 461-470, 1999 (Pubitemid 29135798)
7. Maroni BJ, Steinman TI, Mitch WE: A method for estimating nitrogen intake of patients with chronic renal failure. Kidney Int 27: 58-65, 1985 (Pubitemid 15130686)
8. Marckmann P, Skov L, Rossen K, Dupont A, Damholt MB, Heaf JG, Thomsen HS: Nephrogenic systemic fibrosis: Suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging. J Am Soc Nephrol 17: 2359-2362, 2006 (Pubitemid 44300951)
9. Manunta P, Hamilton BP, Hamlyn JM: Salt intake and depletion increase circulating levels of endogenous ouabain in normal men. Am J Physiol Regul Integr Comp Physiol 290: R553-R559, 2006
10. Ritz E, Koleganova N, Piecha G: Role of sodium intake in the progression of chronic kidney disease. J Ren Nutr 19: 61-62, 2009
11. Sanders PW: Vascular consequences of dietary salt intake. Am J Physiol Renal Physiol 297: F237-F243, 2009
12. He FJ, Markandu ND, Sagnella GA, de Wardener HE, MacGregor GA: Plasma sodium: Ignored and underestimated. Hypertension 45: 98-102, 2005 (Pubitemid 40066421)
13. Sagnella GA, Markandu ND, Buckley MG, Miller MA, Singer DR, MacGregor GA: Hormonal responses to gradual changes in dietary sodium intake in humans. Am J Physiol 256: R1171-R1175, 1989
14. Buckley MG, Saggar-Malik AK, Markandu ND, Sagnella GA, MacGregor GA: Effects of changes in dietary sodium intake on plasma brain natriuretic peptide levels in patients with autosomal dominant polycystic kidney disease. J Hum Hypertens 10: 415-416, 1996 (Pubitemid 26308464)
15. Szinnai G, Morgenthaler NG, Berneis K, Struck J, Muller B, Keller U, Christ-Crain M: Changes in plasma copeptin, the C-terminal portion of arginine vasopressin during water deprivation and excess in healthy subjects. J Clin Endocrinol Metab 92: 3973-3978, 2007 (Pubitemid 47607649)
16. Bagrov AY, Shapiro JI, Fedorova OV: Endogenous cardiotonic steroids: Physiology, pharmacology, and novel therapeutic targets. Pharmacol Rev 61: 9-38, 2009
17. Chea SW, Lee KB: TGF-beta mediated epithelial-mesenchymal transition in autosomal dominant polycystic kidney disease. Yonsei Med J 50: 105-111, 2009
18. Nguyen AN, Wallace DP, Blanco G: Ouabain binds with high affinity to the Na,K-ATPase in human polycystic kidney cells and induces extracellular signal-regulated kinase activation and cell proliferation. J Am Soc Nephrol 18: 46-57, 2007 (Pubitemid 46053421)
19. Wang X, Wu Y, Ward CJ, Harris PC, Torres VE: Vasopressin directly regulates cyst growth in polycystic kidney disease. J Am Soc Nephrol 19: 102-108, 2008
20. Wang X, Ward CJ, Harris PC, Torres VE: Cyclic nucleotide signaling in polycystic kidney disease. Kidney Int 77: 129-140, 2010
21. Havas S, Dickinson BD, Wilson M: The urgent need to reduce sodium consumption. JAMA 298: 1439-1441, 2007 (Pubitemid 47481610)
22. He FJ, MacGregor GA: A comprehensive review on salt and health and current experience of worldwide salt reduction programmes. J Hum Hypertens 23: 363-384, 2009
23. Klahr S, Breyer J, Beck G, Dennis V, Hartman J, Roth D, Steinman T, Wang S, Yamamoto M: Dietary protein restriction, blood pressure control, and the progression of polycystic kidney disease modification of diet in renal disease study group. J Am Soc Nephrol 5: 2037-2047, 1995
24. Okajima F, Sato K, Kimura T: Anti-atherogenic actions of high-density lipoprotein through sphingosine 1-phosphate receptors and scavenger receptor class B type I. Endocr J 56: 317-334, 2009
25. Jo SK, Bajwa A, Awad AS, Lynch KR, Okusa MD: Sphingosine-1-phosphate receptors: Biology and therapeutic potential in kidney disease. Kidney Int 73: 1220-1230, 2008 (Pubitemid 351693151)
26. Chatterjee S, Pandey A: The Yin and Yang of lactosylceramide metabolism: Implications in cell function. Biochim Biophys Acta 1780: 370-382, 2008
27. Deshmukh G, Radin N, Gattone V, Shayman J: Abnormalities of glycosphingolipid sulfatide, and ceramide in the polycystic (cpk/cpk) mouse. J Lipid Res 35: 1611-1618, 1994 (Pubitemid 24291222)
28. Yoo KH, Kim YN, Lee MJ, Seong JK, Park JH: Identification of apolipoproteinA1 reduction in the polycystic kidney by proteomics analysis of the Mxi1-deficient mouse. Proteomics 9: 3824-3832, 2009
29. Bankir L: Antidiuretic action of vasopressin: Quantitative aspects and interaction between V1a and V2 receptor-mediated effects. Cardiovasc Res 51: 372-390, 2001
30. Meijer E, Bakker SJ, de Jong PE, Homan van der Heide JJ, van Son WJ, Struck J, Lems SP, Gansevoort RT: Copeptin, a surrogate marker of vasopressin, is associated with accelerated renal function decline in renal transplant recipients. Transplantation 88: 561-567, 2009
31. Meijer E, Bakker SJ, van der Jagt EJ, de Jong D, Struck J, Gansevoort, RT: Copeptin, a surrogate marker of vasopressin, is associated with disease severity in autosomal dominant polycystic kidney disease. Clin J Am Soc Nephol [Epub ahead of print]
32. Torres VE, Bankir L, Grantham JJ: A case for water in the treatment of polycystic kidney disease. Clin J Am Soc Nephrol 4: 1140-1150, 2009
33. Hebert LA, Greene T, Levey A, Falkenhain ME, Klahr S: High urine volume and low urine osmolality are risk factors for faster progression of renal disease. Am J Kidney Dis 41: 962-971, 2003 (Pubitemid 36532130)